产品简要
公司名称 :
安迪生物R&D
产品类型 :
蛋白
产品名称 :
重组人类VEGFR2/激酶插入区受体Fc嵌合体蛋白
目录 :
357-KD-050
规格 :
50微克
价格 :
405美元
更多信息或购买 :
文章摘录数: 38
参考文献
Yagolovich A, Artykov A, Isakova A, Vorontsova Y, Dolgikh D, Kirpichnikov M, et al. Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity. Int J Mol Sci. 2022;23: pubmed 出版商
Lu L, Chen H, Wang L, Zhao L, Cheng Y, Wang A, et al. A Dual Receptor Targeting- and BBB Penetrating- Peptide Functionalized Polyethyleneimine Nanocomplex for Secretory Endostatin Gene Delivery to Malignant Glioma. Int J Nanomedicine. 2020;15:8875-8892 pubmed 出版商
Fujiwara K, Sasawatari S, Nakai S, Imaeda K, Nagai S, Matsuno Y, et al. Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting Cancers) Therapy for Soft Tissue Sarcoma Patients. Cancers (Basel). 2020;12: pubmed 出版商
Mamer S, Wittenkeller A, Imoukhuede P. VEGF-A splice variants bind VEGFRs with differential affinities. Sci Rep. 2020;10:14413 pubmed 出版商
Seo H, Masuda H, Asagoshi K, Uchiki T, Kawata S, Sasaki G, et al. Streamlined human antibody generation and optimization by exploiting designed immunoglobulin loci in a B cell line. Cell Mol Immunol. 2020;: pubmed 出版商
Njau F, Shushakova N, Schenk H, Wulfmeyer V, Bollin R, Menne J, et al. Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice. PLoS ONE. 2020;15:e0218494 pubmed 出版商
Uslu Ö, Herold J, Kanse S. VEGF-A-Cleavage by FSAP and Inhibition of Neo-Vascularization. Cells. 2019;8: pubmed 出版商
Buczek Thomas J, Rich C, Nugent M. Hypoxia Induced Heparan Sulfate Primes the Extracellular Matrix for Endothelial Cell Recruitment by Facilitating VEGF-Fibronectin Interactions. Int J Mol Sci. 2019;20: pubmed 出版商
Zhang Y, Yong L, Luo Y, Ding X, Xu D, Gao X, et al. Enhancement of HIFU ablation by sonosensitizer-loading liquid fluorocarbon nanoparticles with pre-targeting in a mouse model. Sci Rep. 2019;9:6982 pubmed 出版商
Miller C, Tsuchida C, Zheng Y, Himmelfarb J, Akilesh S. A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia. 2018;20:610-620 pubmed 出版商
Li Y, Hickson J, Ambrosi D, Haasch D, Foster Duke K, Eaton L, et al. ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models. Mol Cancer Ther. 2018;17:1039-1050 pubmed 出版商
Mamer S, Chen S, Weddell J, Palasz A, Wittenkeller A, Kumar M, et al. Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics. Sci Rep. 2017;7:16439 pubmed 出版商
Malara N, Trunzo V, Musolino G, Aprigliano S, Rotta G, Macrina L, et al. Soluble CD54 induces human endothelial cells ex vivo expansion useful for cardiovascular regeneration and tissue engineering application. Int J Cardiol Heart Vasc. 2015;6:48-53 pubmed 出版商
LeBlanc M, Wang W, Chen X, Caberoy N, Guo F, Shen C, et al. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. J Exp Med. 2017;214:1029-1047 pubmed 出版商
Wang J, Qin B, Chen X, Wagner W, Villanueva F. Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles. Mol Pharm. 2017;14:781-790 pubmed 出版商
Ding K, Eaton L, Bowley D, Rieser M, Chang Q, Harris M, et al. Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration. MAbs. 2017;9:269-284 pubmed 出版商
Inoo K, Inagaki R, Fujiwara K, Sasawatari S, Kamigaki T, Nakagawa S, et al. Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. Mol Ther Oncolytics. 2016;3:16024 pubmed
Davydova N, Harris N, Roufail S, Paquet Fifield S, Ishaq M, Streltsov V, et al. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D. J Biol Chem. 2016;291:27265-27278 pubmed 出版商
Han K, Chang J, Lee H, Azar D. Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis. Invest Ophthalmol Vis Sci. 2016;57:3313-22 pubmed 出版商
Teran M, Nugent M. Synergistic Binding of Vascular Endothelial Growth Factor-A and Its Receptors to Heparin Selectively Modulates Complex Affinity. J Biol Chem. 2015;290:16451-62 pubmed 出版商
Fleetwood F, Klint S, Hanze M, Gunneriusson E, Frejd F, StÃ¥hl S, et al. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. Sci Rep. 2014;4:7518 pubmed 出版商
Qi J, Ebrahem Q, Ali M, Cutler A, Bell B, Prayson N, et al. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice. PLoS ONE. 2013;8:e55667 pubmed 出版商
Harris N, Davydova N, Roufail S, Paquet Fifield S, Paavonen K, Karnezis T, et al. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology. J Biol Chem. 2013;288:8176-86 pubmed 出版商
Pfister C, Pfrommer H, Tatagiba M, Roser F. Vascular endothelial growth factor signals through platelet-derived growth factor receptor ? in meningiomas in vitro. Br J Cancer. 2012;107:1702-13 pubmed 出版商
Lorenzon E, Colladel R, Andreuzzi E, Marastoni S, Todaro F, Schiappacassi M, et al. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene. 2012;31:3136-47 pubmed 出版商
Goyal A, Pal N, Concannon M, Paul M, Doran M, Poluzzi C, et al. Endorepellin, the angiostatic module of perlecan, interacts with both the ?2?1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism. J Biol Chem. 2011;286:25947-62 pubmed 出版商
Nishiguchi K, Kataoka K, Kachi S, Komeima K, Terasaki H. Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate. PLoS ONE. 2010;5:e13493 pubmed 出版商
Lorquet S, Berndt S, Blacher S, Gengoux E, Peulen O, Maquoi E, et al. Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment. FASEB J. 2010;24:3782-95 pubmed 出版商
Rennel E, Varey A, Churchill A, Wheatley E, Stewart L, Mather S, et al. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo. Br J Cancer. 2009;101:1183-93 pubmed 出版商
Ponticelli S, Marasco D, Tarallo V, Albuquerque R, Mitola S, Takeda A, et al. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. J Biol Chem. 2008;283:34250-9 pubmed 出版商
Pan Q, Chathery Y, Wu Y, Rathore N, Tong R, Peale F, et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem. 2007;282:24049-56 pubmed
Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med. 2007;204:1431-40 pubmed
Backer M, Levashova Z, Patel V, Jehning B, Claffey K, Blankenberg F, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med. 2007;13:504-9 pubmed
Lake A, Vassy R, Di Benedetto M, Lavigne D, Le Visage C, Perret G, et al. Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1. J Biol Chem. 2006;281:37844-52 pubmed
Ren W, Markel D, Zhang R, Peng X, Wu B, Monica H, et al. Association between UHMWPE particle-induced inflammatory osteoclastogenesis and expression of RANKL, VEGF, and Flt-1 in vivo. Biomaterials. 2006;27:5161-9 pubmed
Getmanova E, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol. 2006;13:549-56 pubmed
Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 2004;6:507-16 pubmed
Seo K, Lee H, Jung B, Ko H, Choi J, Park S, et al. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation. Cancer Res. 2004;64:6482-8 pubmed
产品信息
品牌 :
R&D Systems
master code :
357-KD
SKU号 :
357-KD-050
产品名称 :
重组人类VEGFR2/激酶插入区受体Fc嵌合体蛋白
描述 :
The Recombinant Human VEGFR2/KDR Fc Chimera Protein from R&D Systems is derived from NS0. The Recombinant Human VEGFR2/KDR Fc Chimera Protein has been validated for the following applications: Bioactivity.
靶标 :
VEGFR2/KDR/Flk-1
类别 :
蛋白和酶
单位尺寸 :
50微克
缓冲液 :
Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein.
共轭标签 :
未共轭
纯度 :
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
物种 :
人类
观察到的分子量 :
160-170 kDa, reducing conditions
理论上的分子量 :
110 kDa (monomer)
基因符号 :
激酶插入区受体
功能细节 :
Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 10-40 ng/mL in the presence of 10 ng/mL recombinant human VEGF165.
内毒素说明 :
<0.10 EU per 1 µg of the protein by the LAL method.
accessionNumbers :
AAC16450
应用 :
Bioactivity
来源 :
NS0-derived Recombinant Human VEGFR2/KDR Fc Chimera Protein
美元 :
405美元
别名 :
CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), KRD1, Ly73, Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGF R2, VEGFR, VEGFR2, VEGFR-2
储存 :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
更多信息或购买 :
公司信息
安迪生物R&D
上海市长宁区延安西路726号华敏翰尊国际大厦24A1
info@rndsystemschina.com.cn
http://www.rndsystemschina.com.cn
21 52380373
公司总部: 美国
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.